Aadi Bioscience announces leadership promotions

Aadi Bioscience announced the appointment of Neil Desai, Founder, President and CEO to Executive Chairman and Brendan Delaney, COO, to President and CEO, effective as of January 1, 2023. Desai is the founder of Aadi Bioscience and has served as its President and CEO since 2011. He is the inventor of nab technology and the mTOR inhibitor nab-sirolimus and helped guide the organization through the drug development process leading to approval of FYARRO, the first FDA approved therapy for advanced malignant perivascular epithelioid cell tumor. The Company raised $155M concurrent with a public listing in August 2021 and since that time, has grown to more than 80 employees including the recruitment of a top-notch leadership team. Prior to joining Aadi in September 2021, Delaney served as the Chief Commercial Officer of Constellation Pharma which was acquired by MorphoSys for $1.7B. Prior to joining Constellation, Delaney was the CCO at Immunomedics, where he led the buildout of the marketing, sales, market access, and commercial operations teams. Both Desai and Delaney will serve on the Company’s board of directors after the transition.